Finanzen von Viking Therapeutics Inc (VKTX)VKTXViking Therapeutics Inc

Evaluating the bottom line, Viking Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -88.85%, provide a clear picture of how effectively VKTX converts its operational activities into shareholder value.

In the context of the broader market, VKTX competes directly with industry leaders such as LEGN and IDYA. With a market capitalization of $3.87B, it holds a significant position in the sector. When comparing efficiency, VKTX's gross margin of N/A stands against LEGN's 64.54% and IDYA's 100.00%. Such benchmarking helps identify whether Viking Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported increasing net losses, with Q2 2026 showing a loss of $128 million and an EPS of -1.10, which is better than expected but still indicates ongoing financial struggles.